NASDAQ •
Healthcare •
Biotechnology •
Quote as of 05/29/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization8,827.71 mln
Float23.37 mln
Earnings Date08/10/2026
EPS
7.49
Stretched
P / E
41.49
High premium
Piotroski F-Score
7
/ 9
Strong
Beneish M-Score
-2.27
Borderline
1-Year Forecast
324
Fairly priced
Relative Strength
24
/ 100
Significantly lagging
Business Description
Krystal Biotech is a Pittsburgh-based biotechnology company founded in 2016 that develops and sells gene-based medicines for serious conditions that lack adequate treatment options. Its flagship product, VYJUVEK, is an approved therapy for dystrophic epidermolysis bullosa, a rare and painful skin disorder. The company also has a broad pipeline of treatments in various stages of clinical testing, targeting conditions ranging from cystic fibrosis and eye disease to certain cancers and skin conditions.
